Executive changes at Indivior
UK-based Indivior’s (LSE: INDV) shares rose nearly 4% to 79.05 pence in early trading, after it announced that, effective today, Mark Crossley is appointed chief executive. However, the stock was down 1% at 78.00 pence by late morning.
Shaun Thaxter, in mutual agreement with the company’s board of directors, is stepping down as CEO and executive director.
Mr Crossley has been chief financial and operations officer (CFOO) and executive director of Indivior since February 2017. He was previously chief strategy officer from 2014-2017 and served as finance director where he led the demerger of Indivior from its former parent, Reckitt Benckiser (LSE: RB). Prior to joining Indivior in 2012, he spent 13 years at Procter & Gamble in various finance leadership positions and eight years as an officer in the US Coast Guard.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze